{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-031808","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.396681+00:00","generated_at":"2026-06-21T05:37:48.555912+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vallon Pharmaceuticals to merge with GRI Bio in reverse merger; GRI shareholders to own 83-96.7% of combined company","bullets":["Reverse merger: Vallon Merger Sub merges into GRI; GRI survives as wholly owned subsidiary of Vallon.","Post-closing, GRI shareholders expected to own 83.0% to 96.7% of Vallon; Marc Hertz (GRI CEO) to become CEO.","Pre-merger financing: $3.3M bridge notes (Altium) convertible to ~$2.5M cash; $12.25M equity investment at close.","Lock-up agreements for 90 days after earliest of Rule 144 eligibility or one-year anniversary; termination fee $2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-031808","json":"https://secwatch.observer/filing/0001628280-22-031808.json","markdown":"https://secwatch.observer/filing/0001628280-22-031808.md","text":"https://secwatch.observer/filing/0001628280-22-031808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/0001628280-22-031808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/val-20221213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:37:48.555912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99b4ecae8ee0754e86cdd2b1765d563554f62e02","claim":"GRI Bio, Inc. entered into Agreement and Plan of Merger with GRI Bio, Inc. and Vallon Merger Sub, Inc. (effective 2022-12-13).","evidence_excerpt":"On December 13, 2022, Vallon Pharmaceuticals, Inc. (“Vallon”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with GRI Bio, Inc., a Delaware corporation (“GRI”), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Vallon (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/0001628280-22-031808-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"GRI Bio, Inc. and Vallon Merger Sub, Inc."},{"label":"Effective","value":"2022-12-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}